Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
Ma H, Cheng B, Montanari F, Lue JK, Deng C, Marchi E, Connor O, Sawas A. Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. Therapeutic Advances In Hematology 2020, 11: 2040620720947340. PMID: 33062232, PMCID: PMC7534065, DOI: 10.1177/2040620720947340.Peer-Reviewed Original ResearchAutologous stem cell transplantClassical Hodgkin lymphomaR cHLRefractory classical Hodgkin lymphomaStable diseasePartial responseComplete responseHodgkin's lymphomaPatient populationToxicity profileHigher disease control rateMedian progression-free survivalAlanine transaminase elevationClinical benefit rateLeast equivalent efficacyDisease control rateProgression-free survivalRetrospective case seriesStem cell transplantTolerable toxicity profileFavorable safety profileFavorable toxicity profileContinuous lenalidomideCreatinine elevationTransaminase elevation